MOLECULAR PARTNERS AG (MOLN) News
Filter MOLN News Items
MOLN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MOLN News Highlights
- MOLN's 30 day story count now stands at 3.
- Over the past 12 days, the trend for MOLN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AG, CR and DEC are the most mentioned tickers in articles about MOLN.
Latest MOLN News From Around the Web
Below are the latest news stories about MOLECULAR PARTNERS AG that investors may wish to consider to help them evaluate MOLN as an investment opportunity.
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%Key Insights Significant control over Molecular Partners by retail investors implies that the general public has more... |
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during |
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingInitial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range threeMP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed Phase 1/2a trial remains ongoing with patients being enrolled in fifth of seven planned dose-escalation cohorts ZURICH-S |
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com |
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingMP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose-escalation portion is complete, with final study results expected in H1 2024 Data support continued clinical evaluation of MP0317, including in combination studies ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) |
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionMP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to dateEmerging evidence of antitumor activity observed in dose cohort three, with one responder notedData from ASH abstract released today support clinical proof of concept of MP0533 as a novel tetra-specific T cell engagerExpanded data from the first three cohorts and data from fourth cohort will be prese |
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Exec |
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioMP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned with initial data expected at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023 Radio-DARPin Therapy (RDT) platform continues to progress, supporting the expansion of tar |
Shareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years agoLong term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow... |